Apr 13, 2022
Biomica Announces Agreement with Sheba Medical Center for Joint Microbiome Clinical Research
The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD)
The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD)
Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC333, for the treatment of IBD
Biomica expects to initiate first-in-human, proof-of-concept study later this year
Today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.
